ANNAPOLIS, Md., July 9 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's proposed development plan for SparVax(TM), PharmAthene's next generation recombinant protective antigen (rPA) anthrax vaccine.
In response to amendments to the request for proposal (RFP BARDA 08-15) issued by the U.S. Department of Health and Human Services (HHS) to develop and deliver up to 25 million doses of an rPA vaccine for the Strategic National Stockpile, as previously announced on May 22, 2009 PharmAthene submitted to FDA its development strategy, including the Company's non-clinical and clinical development plans for licensure, for SparVax(TM). In amending the RFP, HHS required that all bidders in the competitive range submit to FDA a comprehensive plan outlining the regulatory strategy for their rPA vaccine. PharmAthene has provided FDA's feedback to the Biomedical Advance Research and Development Authority (BARDA) as required by Amendments 5 and 6 to the RFP.
"We're very pleased by FDA's expedited review of our development plan for SparVax(TM)," said David P. Wright, President and Chief Executive Officer. "FDA was very responsive during the evaluation period, providing written feedback on our development plan in lieu of a formal meeting. We do not believe that FDA's comments on our proposed development plan will require any significant changes to the development program previously submitted to HHS as part of our proposal in response to the RFP, and we look forward to partnering with FDA and BARDA in our continuing efforts to execute on our SparVax(TM) development program."
Mr. Wright continued, "Submissio
|SOURCE PharmAthene, Inc.|
Copyright©2009 PR Newswire.
All rights reserved